A Significant Discrepancy of Uptake between I-131 MIBG and F-18 FDG in a Patient With Malignant Paraganglioma.
- Author:
Jong Su KIM
1
;
Hyun Keun KIM
;
Kyu Young CHOI
;
Hyung Ki PARK
;
Eun Sil KIM
;
Yun Kwon KIM
;
Soyon KIM
;
Young Jung KIM
;
Hyo Jin LEE
Author Information
1. Department of Internal Medicine, National Police Hospital, Seoul, Korea. drsykim@chol.com
- Publication Type:Case Report
- Keywords:
paraganglioma;
F-18 FDG PET/CT;
I-131 MIBG scan
- MeSH:
3-Iodobenzylguanidine*;
Adult;
Electrons;
Humans;
Hydronephrosis;
Lung;
Lymph Nodes;
Neoplasm Metastasis;
Paraganglioma*;
Pelvis;
Positron-Emission Tomography and Computed Tomography;
Spine;
Urinary Bladder
- From:Nuclear Medicine and Molecular Imaging
2007;41(3):247-251
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
A 38-year-old man who was diagnosed with malignant paraganglioma underwent computed tomography (CT) and I-131 metaiodobenzylguanidine (MIBG) san. CT showed extensive lymph node enlargement in right iliac area and retroperitoneum with severe hydronephrosis and mass on posterior bladder wall. However, I-131 MIBG scan didn't showed abnormal uptake. He also underwent F-18 fluorodeoxyglucose (FDG) positron emisson tomography/CT for localizing accurate tumor site. F-18 FDG PET/CT showed multiple metastases of left supraclavicular, hilar, mediastinal para-aortic, inguinal, right iliac lymph nodes, lung, vertebrae, and pelvis. There are a few reports showing that the F-18 FDG PET/CT is helpful for staging and localizing tumor site of patients who are diagnosed with negative on the MIBG scans. Thus, we report a case with paraganglioma which showed negative I-131 MIBG scan, but revealed multiple intense hypermetabolic foci in F-18 FDG PET/CT.
